vaccines and global health :: ethics and policy

….from the Center for Vaccine Ethics and Policy…GE2P2 Global Foundation

Menu

Skip to content

Home
about us
ethics & policy consulting
- CVEP: Fiduciary Transition [May-June 2015]
week in review
- #53112 (no title)
symposium resources
keynotes, papers, panels
- Observations and Comment :: Beware of Kingdoms bearing Gifts – Gavi, Yemen and $25 million from Saudi Arabia :: 3 Nov 2016

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Posted on 2 May 2021 by davidrcurry

Lancet Infectious Diseases
May 2021 Volume 21 Number 5 p579-742, e110-e140
https://www.thelancet.com/journals/laninf/issue/current

Articles
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Raches Ella, et al

Share this:

Facebook
X

Like Loading...

Related

This entry was posted in Uncategorized. Bookmark the permalink.

Post navigation

← Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial

Effectiveness of rotavirus vaccine in preventing transmission of rotavirus from children to household contacts in Malawi →

Search

Archives

Meta

Create account
Log in

Blog at WordPress.com.

Reblog
Subscribe Subscribed
- vaccines and global health :: ethics and policy
- Already have a WordPress.com account? Log in now.

%d